A new report from the AARP Public Policy Institute found that the prices of the top 25 drugs prescribed under Medicare Part D have nearly doubled since they entered the market, outpacing inflation trends.
Senior Healthcare Reporter at Yahoo Finance Anjalee Khemlani joined Brad Smith on Wealth to discuss the results, highlighting significant cost increases for key drugs, including those from Merck (MRK) diabetes drug Janumet, which has soared nearly 300% over its lifespan on the market since 2007.
As Medicare begins to negotiate prices, GLP-1 weight loss drugs like Novo Nordisk (NVO) Ozempic has already seen its prices increase since its beginnings.
For more news and expert analysis on the latest market stocks, check out More Wealth! here.
This article was written by Josh Lynch
